FDA Removes Major HRT Warnings After 20+ Years: What This Means for Women

For more than two decades, hormone replacement therapy carried a reputation shaped more by fear than by science. That changed in a significant way in late 2025, when the U.S. Food and Drug Administration — after an expert review panel and a public comment period — officially announced the removal of the long-standing "black box" warnings from menopausal hormone replacement therapy (HRT) products. The updated labeling took effect in February 2026, and for millions of women, it's long overdue.

What Was the Black Box Warning?

A black box warning is the FDA's most serious safety label — the kind reserved for medications with significant known risks. In 2003, following the Women's Health Initiative (WHI) study, the FDA applied these warnings to HRT products, citing potential risks of breast cancer, cardiovascular disease, and dementia. The result? HRT use dropped sharply, and women experiencing debilitating perimenopause and menopause symptoms were left with few options — or were simply told to endure them.

The problem? The science behind those warnings was always more complicated than the label suggested. The WHI study examined older women, many of whom were well past the onset of menopause, using formulations that don't reflect how hormone therapy is prescribed today. For years, menopause specialists argued that the warnings were overstated and were causing real harm by keeping women away from effective treatment.

What Changed — and Why It Matters

The FDA's November 2025 announcement, which went into effect February 2026, removed black box warnings related to cardiovascular disease, breast cancer, and probable dementia from all four categories of HRT products: combined estrogen-progesterone therapy, systemic estrogen-alone therapy, systemic progestogen-alone therapy, and topical vaginal estrogen.

The updated labeling now emphasizes something menopause specialists have known for years: timing matters. Women who begin hormone therapy before age 60 or within 10 years of menopause onset show a favorable safety profile — and research has associated HRT with reductions in all-cause mortality, fractures, heart attack risk, cognitive decline, and even a lower risk of Alzheimer's disease.

As the FDA noted, only about 2 million women in the U.S. were receiving hormone therapy prescriptions in 2020 — despite roughly 41 million women being in the 45–64 age range. The gap between who could benefit and who was actually receiving care was enormous.

What This Means for Women Seeking Hormone Therapy

If you've been told you're "not a candidate" for hormone therapy, or if your doctor dismissed your menopause symptoms with antidepressants or a "just exercise more" recommendation, this is a pivotal moment to have a new conversation.

The removal of these warnings doesn't mean HRT is right for everyone — it means that for appropriately selected patients, the evidence supports a very different risk-benefit picture than women have been led to believe. The warning for endometrial cancer on systemic estrogen-alone therapy in women with a uterus remains in place, and individualized evaluation is still essential.

Bioidentical Hormone Therapy: A Personalized Approach

At Asclepian Age & Regenerative Care, we've always believed that women deserve better than a one-size-fits-all answer to perimenopause and menopause. Bioidentical Hormone Replacement Therapy (BHRT) uses hormones that are structurally identical to those your body naturally produces — and every treatment plan we develop is tailored to your labs, your symptoms, and your goals.

Whether you're navigating hot flashes, sleep disruption, brain fog, low libido, mood changes, or the longer-term concerns of post-menopausal health, we're here to actually listen — and to help you feel like yourself again.

The science has spoken. You don't have to keep suffering through it.

Ready to start the conversation? Book your consultation today.

John Kurtz, MPAS, PA-C is a certified Physician Associate with 20+ years of medical experience and specialized training in Bioidentical Hormone Replacement Therapy. Asclepian Age & Regenerative Care serves patients in Bluffton, SC and via telemedicine in Georgia.